Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:42:50.347Z.
Calculation as of: 2026-10-06T19:42:50.347Z.
Quote observation: 2026-10-06T19:26:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c2871aed35905ca893ff96a4b2ab646902ae69530b401aedab5470ff00d0a486
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$13.31M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.11M
Price/FCF Ratio
26.90
TTM Avg
28.16
3Y Avg
28.16
5Y Avg
28.16
Market Cap
$14.18M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Optimi Health Corp. (OPTH) | $13.48M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.31M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.12M | N/A | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.85M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.99M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.11M | 26.90 | 28.16 | 28.16 | 28.16 |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.18M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.77M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.63M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.47M | N/A | 4.78 | 4.78 | 4.78 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
